Detailed week-by-week protocol This expanded chart includes practical guidance for each phase: Phase 1: Initiation (Weeks 1-4) Dose: 2 mg once weekly What to expect: Reduced appetite (often noticed within days) Possible mild nausea (usually transient) Some reduction in food cravings Minimal weight loss during this phase Tips: Establish your injection routine Track symptoms in a journal Note your baseline weight and measurements Don't expect dramatic results yet Side effects at this phase: Usually mild if present Most common: slight nausea, mild fullness If severe: contact your provider before escalating Phase 2: First escalation (Weeks 5-8) Dose: 4 mg once weekly What to expect: More noticeable appetite suppression Possible increase in nausea (typically resolves in 1-2 weeks) Beginning of measurable weight loss Some may notice improved energy Tips: Eat smaller, more frequent meals Avoid high-fat and fried foods Stay well-hydrated (minimum 64 oz water daily) If nausea is severe, hold at 2 mg for 2 more weeks Side effects at this phase: GI symptoms often peak here Nausea, occasional vomiting, bloating possible Most symptoms improve by week 7-8 Phase 3: Building dose (Weeks 9-12) Dose: 6 mg once weekly What to expect: Significant appetite reduction Noticeable weight loss (often 5-10% by week 12) Body adapting to medication Side effects often improving from week 5-8 Tips: Continue hydration focus Prioritize protein intake to preserve muscle Consider light exercise if energy permits Monitor for any new symptoms Note: Some protocols skip 6 mg and go directly from 4 mg to 8 mg
When to continue, when to adjust, and when to stop The decision to push through skin sensitivity versus modifying your protocol versus stopping entirely depends on several factors
La experiencia ptima ocurre cuando el entretenimiento se combina con una gestin prudente del bankroll y expectativas realistas sobre la variabilidad de los resultados
PMID 28514449
Most researchers order a monthly supply at a time
June 9, 2026 The Lanier Law Firm Senior Attorney David Rosenband has been appointed to the Plaintiffs Executive Committee in the New Jersey GLP-1 Medications NAION Vision Loss Multicounty Litigation (MCL)
